Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

July 9, 2025

Study Completion Date

July 3, 2028

Conditions
Hypophosphatasia
Interventions
DRUG

ALXN1850

ALXN1850 will be administered via subcutaneous (SC) injection.

DRUG

Placebo

Placebo will be administered via SC injection.

Trial Locations (65)

100

Research Site, Taipei

333

Research Site, Taoyuan District

2065

Research Site, St Leonards

3052

Research Site, Parkville

3168

Research Site, Clayton

4029

Research Site, Herston

10117

Research Site, Berlin

11530

Research Site, Garden City

16499

Research Site, Suwon

18016

Research Site, Granada

20122

Research Site, Milan

20132

Research Site, Milan

20251

Research Site, Hamburg

25240

Research Site, Erzurum

27705

Research Site, Durham

28046

Research Site, Madrid

35128

Research Site, Padua

37134

Research Site, Verona

37212

Research Site, Nashville

38320

Research Site, San Cristóbal de La Laguna

39008

Research Site, Santander

43203

Research Site, Columbus

46202

Research Site, Indianapolis

50139

Research Site, Florence

52621

Research Site, Ramat Gan

53127

Research Site, Bonn

56126

Research Site, Pisa

71013

Research Site, San Giovanni Rotondo

75014

Research Site, Paris

83435

Research Site, Bad Reichenhall

86000

Research Site, Poitiers

97074

Research Site, Würzburg

100039

Research Site, Beijing

100730

Research Site, Beijing

201306

Research Site, Shanghai

266035

Research Site, Qingdao

330006

Research Site, Nanchang

430033

Research Site, Changsha

518053

Research Site, Shenzhen

610041

Research Site, Chengdu

7830604

Research Site, Ashkelon

C1199

Research Site, Ciudad de Buenos Aires

30130-100

Research Site, Belo Horizonte

71625-009

Research Site, Brasília

50740-465

Research Site, Recife

40050-410

Research Site, Salvador

01409-902

Research Site, São Paulo

05403-900

Research Site, São Paulo

T2E 7Z4

Research Site, Calgary

T6G 2H7

Research Site, Edmonton

R3E 3P4

Research Site, Winnepeg

L6M 1M1

Research Site, Oakville

G9A 4P3

Research Site, Trois-Rivières

734-8551

Research Site, Hiroshima

820-8505

Research Site, Iizuka-shi

545-8586

Research Site, Osaka

060-8648

Research Site, Sapporo

425-8505

Research Site, Yaizu-shi

93-338

Research Site, Lodz

03722

Research Site, Seoul

07061

Research Site, Seoul

08003

Research Site, Barcelona

01009

Research Site, Vitoria-Gasteiz

06560

Research Site, Ankara

SW170QT

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY